Answer
The selected product is licensed for PAH in children and adolescents aged 8 to under 18 years, under specialist care. Safety and effectiveness below age 8 have not been established.
Sources for this answer
- Ambrisentan 10 mg film-coated tabletsemc · SmPC Current selected SmPC · Version 2